Companies / Crescent Biopharma, Inc.
Crescent Biopharma, Inc.
Nasdaq: CBIOCIK 1253689WALTHAM, MA
Insider flow · last 90 daysNet sells $1.23M
Financials · FY2025
Ownership
37.1M shares outstanding · as of Jul 27, 2026
Ownership
| 10%+ / strategic | 14.25% | 5,293,514 |
| Institutions | 59.97% | 22,274,099 |
| Public float | 25.78% | 9,576,327 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 15
View all →| Insider | % of shares | Shares |
|---|---|---|
Balcom AlexandraDirector | — | — |
Bispham Barbara HarlinFormerSee Remarks | — | — |
Brumm Joshua TCEOChief Executive Officer · Director | — | — |
Fairmount Funds Management LLCFormerDirector · 10% owner | — | — |
Fairmount Healthcare Fund II L.P.FormerDirector · 10% owner | — | — |
Harwin Peter EvanDirector · 10% owner | — | — |
Im Ellie EunkyungChief Medical Officer | — | — |
Kiselak TomasFormerDirector · 10% owner | — | — |
Lubner David CharlesDirector | — | — |
Lynch RyanFormerSee Remarks | — | — |
Institutional holders 62
View all →| Holder | Value | % of shares |
|---|---|---|
| $50.49M | 7.40% | |
| $49.02M | 11.13% | |
| $32.59M | 7.40% | |
| $27.74M | 4.07% | |
| $25.30M | 5.74% | |
| $22.89M | 3.42% | |
| $21.31M | 3.12% | |
| $19.90M | 4.52% | |
| $17.79M | 4.04% | |
| $13.97M | 3.17% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Add | Common stock | $25.69M | +1.4M +1251.68% | 1,510,033 4.07% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $20.93M | +1.2M +1064.30% | 1,271,762 3.42% of shares | medium |
| Q2 2025 as of | Boxer Capital Management, LLC 13F manager | New | Common stock | $7.32M | +454K | 453,686 1.22% of shares | medium |
| Q2 2026 as of | Remedium Capital Partners, LLC 13F manager | New | Common stock | $6.50M | +361K | 361,250 0.97% of shares | medium |
| Q1 2026 as of | Tang Capital Management, LLC 13F manager | Add | Common stock | $5.28M | +288K +32.97% | 1,160,000 3.12% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $5.21M | +289K +1103.75% | 315,587 0.85% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common stock | $4.81M | +262K +422.85% | 323,553 0.87% of shares | low |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | Trim | Common stock | $-4.53M | -247K -54.39% | 206,942 0.56% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Fmr LLC | Passive13G/A | — |
| Venrock Healthcare Capital Partners III, L.P. | Passive13G/A | — |
| Vestal Point Capital, LP | Passive13G | — |
| Balyasny Asset Management L.P. | Passive13G | — |
| Tang Capital Management, LLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| CBIO | — | 38000Q201 |
| CBIO | — | G2545C104 |